June, 2025

Newsletter

Intoinworld

A People-Centric Company, IntoInWorld Co., Ltd.
"Connecting People, Advancing Clinical Value."
At IntoInWorld, we strive to be a trusted bridge, safely delivering the value of medical advancements to people. Guided by a human-centered approach, we are committed to growing alongside our clients as true partners.
Established in 2015, IntoInWorld Co., Ltd. is a Contract Research Organization (CRO) specializing in clinical trials across pharmaceuticals, biotechnology, medical devices, investigator-initiated trials (IIT), and observational studies (OS).
With expertise spanning Phase 1 to Phase 3 trials and post-marketing surveillance (PMS), our dedicated team of experienced professionals operates with systematic processes that meet global standards, ensuring accurate and reliable outcomes.

Trump's Global Policy Risks: An Opportunity for South Korea's Pharmaceutical and Biotech Industry?

With the return of the U.S. President and a strengthened protectionist stance, South Korea's pharmaceutical and biotech sectors are poised for potential indirect benefits. While policy uncertainty may lead to stock price adjustments in the first half of the year, a recovery is anticipated in the second half as uncertainties subside. Tariff risks remain low, and supply chain restructuring and reshoring could create opportunities for domestic Contract Development and Manufacturing Organizations (CDMOs). Drug price reductions, primarily targeting global pharmaceutical companies, are expected to have limited impact on South Korea's industry.

Aiming to Build a Biotech Powerhouse, Yet the Approval Department Remains a Temporary Task Force

The government is pushing to nurture pharmaceutical and biotech unicorns and expand technology exports, but the biopharmaceutical approval task force continues to operate as a temporary organization. As approvals surge with market growth, the industry is increasingly calling for the task force to transition into a permanent entity to ensure regulatory consistency and stronger communication.

K-Bio and Pharma Thrive in First Half: R&D and Global Expansion as Key Growth Drivers

In the first half of 2025, South Korea's pharmaceutical and biotech companies saw improved performance driven by advancements in new drug development and expanded overseas operations. Some companies generated over 90% of their revenue from international markets, with technology transfers and milestone payments further boosting results.
In the second half, despite variables such as tariff policies, Middle East conflicts, and interest rate cuts, record-high performance is anticipated due to sustained R&D investment and strengthened global operations. Experts suggest the potential for technology exports to exceed 10 trillion KRW, noting that companies with significant overseas exposure are poised for growth, while those focused on domestic markets may face stagnation concerns.

02-2038-8082 www.intoinworld.com bd@intoinworld.kr

APRIL, 2025

Newsletter

Intoinworld

"Biotech Enters the AI Platform Era": Evolving R&D Landscape

From 2024 to 2028, the government is investing 34.8 billion KRW to prioritize AI-driven drug development as one of its top 10 focus areas. Pharmaceutical and biotech companies are leveraging AI platforms to advance drug discovery, candidate identification, clinical trial design, and production efficiency. The industry recognizes AI as a pivotal force in revolutionizing drug development and enhancing global competitiveness.

The Era of 'Non-Animal Testing' Approaches: How Prepared Are the Government and Pharmaceutical Industry?

As South Korea's Ministry of Food and Drug Safety (MFDS) discusses the phased elimination of animal testing, the development of alternative testing methods, such as AI and organoids, is gaining momentum. Organoids are drawing attention for their high human relevance, though challenges remain in long-term culturing. The government is promoting research support and legislation through 2028, with calls for expanded collaboration, investment, and refined policy guidelines to further advance these efforts.



A 'Deepseek' Moment for Biotech? Foreign Companies Are Snapping Up Chinese Novel Drugs

중국 바이오 기업들이 글로벌 시장에 본격 진출하고 있다. A사는 B사와 48억 달러 규모 항암제 'S물질' 기술수출 계약을 체결했으며, 이는 중국 최대 규모다. S물질은 키트루다 경쟁 후보로 주목받고 있다. D사, G사 등도 대형 기술이전 계약을 성사시켰고, ASCO 발표 이후 주가가 급등하며 H사는 흑자 전환, I사는 시총 22조8,000억 원을 돌파했다. 중국 신약은 '계열 내 최고' 수준의 경쟁력을 갖췄다는 평가다.

02-2038-8082 www.intoinworld.com bd@intoinworld.kr